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Abstract
Background: Current treatment options for castration- and treatment-resistant prostate cancer are limited and novel
approaches are desperately needed. Our recent results from a systematic chemical biology sensitivity screen covering most
known drugs and drug-like molecules indicated that aldehyde dehydrogenase inhibitor disulfiram is one of the most potent
cancer-specific inhibitors of prostate cancer cell growth, including TMPRSS2-ERG fusion positive cancers. However, the
results revealed that disulfiram alone does not block tumor growth in vivo nor induce apoptosis in vitro, indicating that
combinatorial approaches may be required to enhance the anti-neoplastic effects.
Methods and Findings: In this study, we utilized a chemical biology drug sensitivity screen to explore disulfiram
mechanistic details and to identify compounds potentiating the effect of disulfiram in TMPRSS2-ERG fusion positive prostate
cancer cells. In total, 3357 compounds including current chemotherapeutic agents as well as drug-like small molecular
compounds were screened alone and in combination with disulfiram. Interestingly, the results indicated that androgenic
and antioxidative compounds antagonized disulfiram effect whereas inhibitors of receptor tyrosine kinase, proteasome,
topoisomerase II, glucosylceramide synthase or cell cycle were among compounds sensitizing prostate cancer cells to
disulfiram. The combination of disulfiram and an antiangiogenic agent sunitinib was studied in more detail, since both are
already in clinical use in humans. Disulfiram-sunitinib combination induced apoptosis and reduced androgen receptor
protein expression more than either of the compounds alone. Moreover, combinatorial exposure reduced metastatic
characteristics such as cell migration and 3D cell invasion as well as induced epithelial differentiation shown as elevated E-
cadherin expression.
Conclusions: Taken together, our results propose novel combinatorial approaches to inhibit prostate cancer cell growth.
Disulfiram-sunitinib combination was identified as one of the potent synergistic approaches. Since sunitinib alone has been
reported to lack efficacy in prostate cancer clinical trials, our results provide a rationale for novel combinatorial approach to
target prostate cancer more efficiently.
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Introduction
Prostate cancer is the most frequent cancer and the second
leading cause of cancer deaths in male population in the Western
world [1]. Since most prostate cancer patients eventually become
resistant to currently existing drugs such as anti-androgens and
later also to cytotoxic agents, novel drugs and combinatorial
approaches are needed. We have recently performed a chemical
biology compound screen to systemically test the sensitivities of
4910 known drugs and drug-like small molecules in non-malignant
and malignant prostate cancer cells [2]. Aldehyde dehydrogenase
(ALDH) inhibitor disulfiram was among four cancer selective
inhibitors identified blocking the growth of cultured TMPRSS2-
ERG fusion positive VCaP cells at nanomolar concentration as
well as reducing VCaP xenograft growth in vivo [2]. Recently, the
growth inhibitory potential of disulfiram in prostate cancer has
been confirmed in an independent high-throughput compound
screen in vitro and xenograft studies in vivo [3,4].
Disulfiram is an ALDH inhibitor that has been long-term used
as an alcohol deterrent in the clinics. In addition to prostate
cancer, disulfiram has also been shown to have anticancer effect in
breast, myeloma, leukemia, lung cancer, cervical adenocarcinoma,
melanoma, neuroblastoma and colorectal cancer [5–11]. Current-
ly, disulfiram is in Phase I clinical trials in metastatic melanoma, in
hormone refractory cancers with lung and liver metastases (www.
clinicaltrials.gov, identifiers NCT00256230 and NCT00742911)
as well as in prostate cancer (identifier: NCT01118741). In
cultured prostate cancer cells, disulfiram induces oxidative stress,
reduces ALDH and DNA methyltransferase (DNMT) activities as
well as inhibits DNA replication [2,4,12]. In breast cancer,
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disulfiram and copper co-exposure inhibits NF-kB activity,
increases reactive oxygen species and the number of cancer stem
cells (CSC) [13]. Moreover, inhibition of ALDH activity has been
suggested as a potential mean to reduce cancer stem cells and to
overcome drug resistance [14]. Our previous results indicated that
although disulfiram reduced VCaP cell xenograft growth approx-
imately by 40%, it was not able to block it [2]. Similar results have
been obtained in in human bone metastatic LNCaP C4-2B
xenografts [4]. In addition, disulfiram exposure alone was not
sufficient to induce apoptosis in prostate cancer cells [2]. Thus, in
this study, we performed a combinatorial sensitivity screen in ERG
positive prostate cancer cells to explore disulfiram mechanism of
action in more detail. Moreover, the aim was to identify potential
agents synergizing with disulfiram in prostate cancer cells. In total,
3357 compounds including current chemotherapeutic agents and
drug-like small molecular compounds were studied alone and in
combination with disulfiram. The molecular and phenotypic
alterations were explored with one of the most potent disulfiram
sensitizer, sunitinib.
Materials and Methods
Cells
The TMPRSS2-ERG gene fusion and AR positive prostate
carcinoma cell line VCaP was received from Drs. Adrie van
Bokhoven (University of Colorado Health Sciences Center,
Denver, Colorado) and Kenneth Pienta (University of Michigan,
Michigan) and were grown in Dulbecco’s Modified Eagle’s
Medium [15]. Prostate carcinoma PC-3 cells were purchased
from American Type Culture Collection (LGC Promochem AB,
Bora˚s, Sweden) and grown according to provider’s instructions.
Compounds
Disulfiram was purchased from Fluka (Munich, Germany) and
diluted in DMSO. Sunitinib was purchased from LC Laboratories
(Woburn, USA) and diluted in DMSO.
High-throughput Compound Sensitivity Screen
A high-throughput compound sensitivity screen with the library
of 3357 compounds alone and in combination with disulfiram was
performed in VCaP cells. The library included current che-
motherapeutics and small molecular compounds of commercial
compound libraries LOPAC (1,280 existing Food and Drug
Administration–approved drugs and other compounds with
pharmacologically relevant structures; 1 and 0.1 mmol/L), Micro-
source Spectrum (2,000 compounds including most of the known
drugs and other bioactive compounds and natural products; 1 and
0.1 mmol/L), and an inhouse library (77 experimental compounds;
10, 1, and 0.1 mmol/L). In the screen, EC50 value of disulfiram
(90 nM) was used. The cell viability was determined after 3-day
incubation using a CellTiter-Glo (CTG) fluorescent cell viability
assay (Promega, Inc.). The cell viability results were normalized
using a loess method as previously described [2]. The compounds
that qualified as hits inhibited cell viability by at least three
standard deviations from the median of the DMSO controls.
Cell Viability and Apoptosis Assays
Cell viability and apoptosis assays were performed on 384-well
plates (Falcon). 2,000 cells per well were plated in 35 ml of their
respective growth media and left to attach overnight. Compound
dilutions were added to the cells in 15 ml and incubated for 48 h.
Cell viability was determined using the CTG cell viability assay
(Promega, Inc.). Induction of caspase-3 and 7 activities was
detected with homogenous Apo-ONE assay (Promega, Madison,
WI). Cell viability and apoptosis assays were then performed
according to the manufacturer’s instructions. Briefly, in the cell
viability assay, 25 ml of activated CTG reagent was added to each
Figure 1. Combinatorial high-throughput cell viability screen to identify disulfiram modulating compounds. Loess-normalized
CellTiter-Glo results with 3357 compounds screened in the absence (y-axis) and presence (x-axis) of disulfiram (EC50 90 nM) in VCaP prostate cancer
cells. Each dot represents result obtained with one compound. Data points qualifying as disulfiram sensitizing (squares below the trendline) and
rescuing (triangles above the trendline) compounds are indicated. Result with sunitinib is indicated by an arrow.
doi:10.1371/journal.pone.0051470.g001
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well, the plate was incubated for 30 min at RT/150 rpm and the
luminescence signal (700 nm) was quantified using Envision
Multilabel Plate Reader (Perkin-Elmer, Massachusetts, MA). For
the apoptosis assay, 25 ml of media was taken out from each well
and 25 ml of ApoONE reagent was added into each well. The
plate was incubated for 2 hours at RT and the fluorometric signal
(excitation FITC 499 nm, emission FITC 521 nm) was quantified
using Envision Multilabel Plate Reader. The average lumines-
cence or fluorometric signal from the six replicate compound
treated wells were divided by the average signal of six DMSO
vehicle control treated wells to determine fold changes.
Statistical Analyses
The hit criteria in compound screen (score lower than 23 SD
from the median) correspond to a P value of ,0.01. Statistical
analyses of all results were done by using the Student’s t-test.
These results are presented as the mean 6 SD. The following P
values were used to show statistical significance: *, P,0.05;
**, P,0.01; and ***, P,0.005.
Determination of Combinatorial Drug Effects
The nature of interaction and the degree of synergy between
disulfiram and sunitinib were analyzed using the combination
index method [16]. The concentration dependence of antiproli-
ferative effects was determined for both compounds, either alone
or in combination. Fraction affected (Fa) was defined as the
fraction of cells affected by the given concentration of compounds
alone or in combination. Fa = 0 was determined based on DMSO
control and Fa = 1 on staurosporine (1 mM) response (no viable
cells left). The data was analyzed with Calcusyn software (Biosoft,
Cambridge, UK), and the combination index (CI) was calculated
from the median effect plots according to equation CI = (D)1/
(DX)1+(D)2/(DX)2, where (DX)1 and (DX)2 are the concentra-
tions of compounds D1 and D2 needed to produce a given level of
antiproliferative effect when used alone, whereas (D)1 and (D)2 are
their concentrations that produce the same effect when used in
combination. A combination index of 0.9–1.1 indicates additive
interaction, values below 0.9 indicate synergism, and values over
1.1 indicate antagonism.
Table 1. Compounds sensitizing the effect of disulfiram.
Compound
Concentration in
the screen Description
Inhibition of cell
viability alone (%)
Inhibition of cell viability in
combination with DSF EC50
(%)
Bortezomib 2.6 mg/ml Proteasome inhibitor 268 280
CGP-74514A hydrochloride 1 mM Cyclin-dependent kinase 1
(Cdk1) inhibitor
210 232
Epirubicin hydrochloride 10 mM Topoisomerase II inhibitor 257 265
Phorbol 12-myristate 13-acetate 1 mM Protein kinase C (PKC) activator 260 266
Sunitinib 10 mM Receptor tyrosine kinase
(RTK) inhibitor
215 235
Threo-1-Phenyl-2-decanoylamino-3-
morpholino-1-propanol hydrochloride
0.1 mM Glucosylceramide synthase
(GCS) inhibitor
249 258
doi:10.1371/journal.pone.0051470.t001
Table 2. Compounds rescuing the effect of disulfiram.
Compound
Concentration
in the screen Description
Inhibition of cell
viability alone (%)
Inhibition of cell viability in
combination with DSF EC50
(%)
4-Androstene-3,17-dione 1 mM Testosterone precursor and
metabolite with androgenic
activity
224 28
5-alpha-Androstane-3-alpha,17-beta-
diol
1 mM Testosterone metabolite 233 212
Androsterone 1 mM Anabolic steroid 221 28
Astaxanthin 1 mM Antioxidant 215 21
Cetuximab 0.2 mg/ml Epidermal growth factor
receptor (EGFR) inhibitor
239 226
Dequalinium analog, C-14 linker 1 mM Protein kinase C-alpha
(PKC-alpha) inhibitor
280 271
Tyrphostin AG 528 1 mM Epidermal growth factor
receptor (EGFR) inhibitor
232 220
Vinorelbine ditartrate 10 mg/ml Microtubule assembly inhibitor 267 259
doi:10.1371/journal.pone.0051470.t002
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RNA Extraction and Quantitative Reverse Transcriptase
PCR
Total RNA was extracted from cultured cells using RNeasy
(Qiagen) according to the manufacturer’s protocol. Reverse
transcription using 500 ng of total RNA was performed using
Applied Biosystems cDNA synthesis kit. TaqMan gene expression
probes and primers from the Universal Probe Library (Roche
Diagnostics, Espoo, Finland) were used to study androgen receptor
(AR), prostate specific antigen (PSA), ERG, MYC and b-actin
mRNA expression. Primer sequences are listed in Table S1. Real-
time quantitative PCR was performed using ABI Prism 7900
(Applied Biosystems, Foster City, CA). Quantitation was carried
out using the DDCT method with RQ manager 1.2 software
(Applied Biosystems). b-actin was used as an endogenous control.
Average expression of the DMSO exposed control samples was
considered for the calculation of the fold changes. Two to four
replicate samples were studied for quantitation of mRNA
expression.
Western Blot Analysis and Subcellular Proteome
Extraction
For protein extraction and Western blot analysis, VCaP cells
were plated at 70% confluency and left to attach over night before
treatments. Whole-cell lysates were prepared using lysis buffer
(62.5 mM Tris, 1% SDS, 5%, b-mercaptoethanol, 10% glycerol
and bromophenol blue). Three replicative samples were studied
for quantitation of protein expression. Specific antibodies recog-
nizing AR (1:1000 dilution, mouse monoclonal, Labvision,
Fremont, CA) or PSA (1:1000, rabbit polyclonal, DakoCytoma-
tion, Denmark) were used. b-actin (1:4000, mouse monoclonal,
Sigma) was used as a loading control. Signals were detected with
1:4000 dilutions of appropriate HRP-conjugated secondary
antibodies (all from Invitrogen Molecular Probes, Carlsbad, CA)
followed by visualization with the enhanced chemiluminescence
reagent (Amersham Biosciences, Little Chalfont, UK). The
obtained signals were densitometrically analyzed with GeneTools
software (SynGene, Synoptics Ltd, Cambridge, UK).
Immunofluorescence
Immunofluorescence staining of VCaP cells was carried out as
previously described [12]. Images were taken with 636magnifi-
cation using a Zeiss Axiovert 200 M fluorescence microscope (Carl
Zeiss AG, Oberkochen, Germany).
Wound Healing Assay
The effect of disulfiram (1 mM) and sunitinib (5 mM) alone and
in combination on prostate cancer cell migration was studied using
a wound-healing assay. PC-3 cells were plated on 96-well plates
(Essen ImageLock, Essen Instruments, Birmingham, UK) and
a wound was scratched with wound scratcher (Essen Instruments).
Compounds and appropriate controls were added immediately
after wound scratching and wound confluence was monitored with
Incucyte Live-Cell Imaging System and software (Essen Instru-
ments). Wound closure was measured every hour for 24 h by
comparing the mean relative wound density of three biological
replicates in each experiment.
3D Assay
Cells were cultured in 3D on Matrigel on uncoated Angiogen-
esis m-slides (Ibidi Gmbh, Germany). The bottom wells were filled
with 10 ml of Matrigel (50%) in culture medium and incubated for
30 min in 37uC. The cells (1000 cells/well) were then plated and
Figure 2. Illustration of disulfiram (DSF), sunitinib and disulfiram-sunitinib co-exposure induced effects on prostate cell viability.
Relative cell viability results in A) VCaP and B) PC-3 prostate cancer cells as well as in non-malignant C) RWPE-1 and D) EP156T cells. Asterisks indicate
the statistical significance: *, P,0.05; **, P,0.01; and ***, P,0.005.
doi:10.1371/journal.pone.0051470.g002
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let to attach for 1–2 hours in 37uC. The second layer of Matrigel
in culture medium (25%) was added and the plates were incubated
in 37uC. Disulfiram (1 mM), sunitinib (5 mM) or disulfiram-
sunitinib combination was added after 4 days of incubation and
maintained for up to 7 days. Spheroids were monitored in real-
time by live-cell imaging (Incucyte, Essen Instruments; 106
Figure 3. Sunitinib shows synergism with disulfiram in prostate cancer cells. A) Cell morphology in response to disulfiram (1 mM) and
sunitinib (5 mM) exposures alone and in combination. B) Presentation of combination index (CI) and fraction of cells affected (Fa) by compound
exposures in different concentrations (500 nM, 1 mM, 5 mM and 10 mM) in VCaP prostate cancer cells. CI values for each concentration: 500 mM: 0.92,
1 mM: 0.19, 5 mM: 0.21, 10 mM: 0.40. C) Caspase 3/7 activities in response to compound exposures. Asterisks indicate the statistical significance: ***,
P,0.005.
doi:10.1371/journal.pone.0051470.g003
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objective), acquiring 1 image/h. The area of 3D structures in the
images was compared to the total image area (in percentages) to
quantitate potential effects of the compounds on cell growth.
Results
Chemical Biology compound Sensitivity Screen Identifies
Synergistic Agents with Disulfiram
Chemical biology compound screen approach was utilized to
study the mechanism of disulfiram reduced cell viability in prostate
cancer cells and to explore potential synergistic interactions of
disulfiram and screened compounds. Library of 3357 compounds
including most of the known drugs and drug-like small molecular
compounds was screened alone and in combination with di-
sulfiram in VCaP prostate cancer cells. The cell viability results in
the absence (DMSO control) or presence of disulfiram (EC50,
90 nM) were compared. As expected, several compounds inhibited
VCaP cell growth (Fig. 1). However, only 15 compounds showed
a combination effect with disulfiram. In total, six compounds
sensitised VCaP cells to disulfiram: threo-1-Phenyl-2-decanoyla-
mino-3-morpholino-1-propanol hydrochloride, bortezomib, CGP-
74514A hydrochloride, epirubicin hydrochloride, phorbol 12-
myristate 13-acetate and sunitinib (Table 1). In contrast, 9
compounds rescued disulfiram induced antiproliferative effect
Figure 4. Disulfiram-sunitinib co-exposure reduces AR signalling in VCaP prostate cancer cells. The expression of A) AR, B) PSA, C) ERG,
D) MYC mRNA in response to disulfiram (DSF) and sunitinib (Su) exposures alone and in combination. E) AR and PSA protein expression in response to
compound exposures alone and in combination. F) Quantification of AR protein expression in response to 6- and 24 h compound exposures.
Asterisks indicate the statistical significance: *, P,0.05; **, P,0.01; and ***, P,0.005.
doi:10.1371/journal.pone.0051470.g004
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(Table 2). Interestingly, these compounds included androgenic
compounds 4-Androstene-3,17-dione, 5-alpha-Androstane-3-al-
pha,17-beta-diol and androsterone as well as antioxidant astax-
anthin. Thus, the results indicate that disulfiram reduced cell
proliferation may be antagonized with androgen activation or
antioxidants. Moreover, PKC activator phorbol 12-myristate 13-
acetate was among drugs sensitizing disulfiram effect and PKC
inactivator dequalinium analog, C-14 linker, was among drugs
rescuing disulfiram effect, indicating that PKC may play a role in
disulfiram response. Furthermore, disulfiram effect may be
potentiated via inhibition of receptor tyrosine kinases, proteasome,
topoisomerase II, glucosylceramide synthase or cell cycle (Table 1)
whereas inhibition of epidermal growth factor receptor seems not
to be a potent strategy to enhance the effect of disulfiram (Table 2).
Sunitinib and Disulfiram Cotreatment Show Synergism
Interestingly, sunitinib, an anti-angiogenic agent, potentiated
the disulfiram induced growth-inhibitory effect. Sunitinib inhibits
the activity of multiple tyrosine kinases such as VEGFR-1, -2 and -
3, PDGFR-a and -b, c-Kit, Ret and Flt-3 [17]. It has been shown
to have anti-neoplastic activities in a variety of malignancies such
as hepatocellular cancer, pancreatic neuroendocrine tumors, and
non-small cell lung cancer. Sunitinib is licenced to metastatic renal
cell carcinoma and gastrointestinal tumors [18–20]. In prostate
cancer, sunitinib reduces significantly the growth of castration-
resistant prostate cancer, both in preclinical and clinical settings
[21,22]. However, a recent phase III study of sunitinib in prostate
cancer failed due to lack of efficacy in castration-resistant prostate
cancer (identifier: NCT00676650). Since sunitinib has already
been studied in clinical trials in prostate cancer patients, sunitinib-
disulfiram combination was selected for further in vitro studies.
To validate the combinatorial anti-proliferative effect of
sunitinib in prostate cancer cells, the effect of disulfiram and
sunitinib alone and in combination was studied in VCaP and PC-3
prostate cancer cells. The results indicated that disulfiram and
sunitinib co-exposure reduced VCaP cell viability more than either
of the compounds alone (Fig. 2A). In PC–3 cells, the anti-
proliferative effect was seen only at higher concentrations in
response to sunitinib or disulfiram-sunitinib co-exposure (Fig. 2B).
To identify whether the synergism in VCaP cells is caused simply
due to increased cytotoxicity, the effect of disulfiram, sunitinib or
disulfiram-sunitinib co-exposure was studied in non-malignant
RWPE-1 and EP156T prostate epithelial cells. The results showed
that cell viability was decreased only at highest (10 mM)
concentration in RWPE-1 and EP156T cells (Fig. 2C and D),
indicating that the increase in overall cell toxicity does not explain
the combinatorial response in VCaP cells.
To compare the effects of disulfiram (1 mM) and sunitinib
(5 mM) alone and in combination on VCaP cell morphology,
Incucyte live cell analysis was performed. Cells were exposed to
compounds for 48 hours. Clear morphological changes were
observed in response to all compound exposures (Fig. 3A). In
particular, sunitinib caused cells to attach to each other since no
individual cells were seen in sunitinib exposure cells. In response to
disulfiram-sunitinib co-treatment, cells were also attached with
each other, but there was clearly less viable cells left (Fig. 3A).
Combination index (CI) was determined at various drug
concentrations (500 nM, 1 mM, 5 mM and 10 mM) based on cell
viability results in VCaP cells. The results indicated that disulfiram
Figure 5. Disulfiram-sunitinib combination reduces E-cadherin expression. E-cadherin (red) and F-actin (yellow) expressions in response to
compound treatments. DNA was stained with DAPI (blue).
doi:10.1371/journal.pone.0051470.g005
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and sunitinib showed synergism at all concentrations tested (CI
,1) (Fig. 3B). The lowest CI-values were seen in concentrations of
1 mM and 5 mM (CI 0.19 and 0.21). Sunitinib concentration of
5 mM was chosen for further combination experiments based on
CI and cell viability results as well as previous sunitinib in vitro
studies in prostate cancer cells [23–25].
Sunitinib and Disulfiram Cotreatment Induces Apoptosis
in Prostate Cancer Cells
To identify whether disulfiram and sunitinib exposure induces
apoptosis, caspase 3 and 7 activities were determined by
a quantitative fluorometric assay. Caspase activity was measured
in response to disulfiram (1 mM) and sunitinib (5 mM) exposure for
48 hours alone and in combination in VCaP cells. Interestingly,
neither disulfiram nor sunitinib alone was able to induce apoptosis.
However, a significant induction of apoptosis was seen in response
to disulfiram-sunitinib combination treatment (Fig. 3C). Taken
together, sunitinib shows synergistic growth inhibitory effects with
disulfiram and the combination of these two compounds induce
apoptosis more than either of the compounds alone.
Sunitinib Reduces the Expression of Androgen receptor
(AR), Prostate Specific Antigen (PSA), ERG and MYC in
ERG positive prostate cancer cells
To identify the first molecular changes in response to disulfiram
and sunitinib, mRNA expression of prostate cancer oncogenes
AR, PSA, ERG and MYC was studied in disulfiram (1 mM),
sunitinib (5 mM) or disulfiram-sunitinib co-exposed VCaP cells at
3-hour time point. Interestingly, the results indicated that sunitinib
significantly reduced AR, PSA, ERG and MYC levels (approx-
imately by 40%) whereas disulfiram alone did not have major
effect (Fig. 4A, B, C and D). The results with disulfiram are in
accordance with our previous study [2]. However, there were no
indications for a combinatorial effect of disulfiram and sunitinib on
reducing the expression of these oncogenes at mRNA level.
To find out whether changes can be detected at protein level,
AR was studied in response to longer exposures (6 and 24 hours) of
disulfiram and sunitinib alone and in combination. Interestingly,
only a slight reduction of AR was observed in response to sunitinib
alone, and no decrease in AR protein expression was seen in
response to disulfiram alone. However, a clear reduction of AR
protein expression (20 and 50%) was observed in response to the
combination exposure of disulfiram and sunitinib at 6- and 24-
hour time points (Fig. 4E and F). Moreover, similar decrease in
AR regulated PSA protein levels were observed (Fig. 4E). Taken
together, these results indicate that sunitinib reduces androgen
signalling in prostate cancer cells especially when combined with
disulfiram. However, further analysis is needed to identify whether
disulfiram and sunitinib act synergistically through androgen
signalling.
Disulfiram and Sunitinib Cotreatment Induces E-cadherin
Expression
The results from microscopic cell morphology analysis sug-
gested that VCaP cells were more attached to each other in
response to either sunitinib or disulfiram and sunitinib co-exposure
compared to disulfiram exposure alone (Fig. 3A). To identify
whether these phenotypes were due to induction of cell adhesion
molecule E-cadherin, immunochemical staining was performed.
The results indicated that disulfiram and sunitinib cotreatment
induced E-cadherin expression more than either of the compounds
alone (Fig. 5). E-cadherin is commonly known marker for cancer
cell differentiation and it is downregulated in invasive prostatic
carcinoma [26]. We have previously shown that induction of E-
cadherin expression is associated with reduced cell proliferation in
ERG positive VCaP prostate cancer cells [27,28]. These results
indicate that morphological phenotype seen in response to
sunitinib-disulfiram cotreatment correlates with elevated E-cad-
herin expression in VCaP prostate cancer cells.
Disulfiram and Sunitinib Cotreatment Reduces Prostate
Cancer Cell Migration
To study whether disulfiram and sunitinib cotreatment affects
prostate cancer cell migration, live cell cell migration assay was
done. In the assay, PC-3 cells were used as prostate cancer model,
since VCaP cells do not migrate in this assay. The results indicated
that disulfiram-sunitinib co-exposure reduced cell migration more
than either one of the compounds alone (Fig. 6). The migration
was reduced significantly in disulfiram and sunitinib co-exposed
prostate cancer cells at 12- and 24-hour time points (by 20 and
30% compared to DMSO control). Significant decrease in cell
migration was seen also in disulfiram and sunitinib exposed cells at
24-hour time point (Fig. 6B). PC-3 cell confluence was not
significantly decreased at these time points, indicating that the
Figure 6. The effect of disulfiram and sunitinib cotreatment on
PC-3 cell migration. Cells were automatically imaged once every
hour after wound scratching. Wound closure effect was calculated as
wound confluence in response 6-, 12- and 24 h exposures of the
compounds A) Wound healing in response to compound exposures for
24 hours. Black area represents the wound edges in the beginning of
the assay. B) Quantification of cells entering the wound area. Asterisks
indicate the statistical significance: *, P,0.05; **, P,0.01; and ***,
P,0.005.
doi:10.1371/journal.pone.0051470.g006
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reduction of cell migration does not result due to reduced cell
proliferation (Figure S1). Thus, the results showed that disulfiram-
sunitinib co-exposure reduces prostate cancer cell migration more
than either of the compounds alone.
Disulfiram and Sunitinib Combination Reduces Prostate
Cancer Cell Invasion in 3D Culture
The effect of disulfiram and sunitinib cotreatment was studied
in PC-3 3D spheroid model [29]. The spheroids were grown on
Matrigel for 4 days and disulfiram (1 mM) and sunitinib (5 mM)
alone and in combination were added to the cells and the cell
morphology was monitored for 7 days using live-cell imaging. The
results are shown in Figure 7. Disulfiram alone was able to reduce
cells from invading 3D structure, but it was not able to reduce the
growth of the cells inside the lumen (Fig. 7A). In contrast, sunitinib
treated spheroids were smaller while cell invasion was not blocked.
Interestingly, the combination treatment reduced the amount of
invasive protrusions as well as the size of the spheroids. The area of
cells in the images (% of total area) in response to compound
treatments for 7 days in 3D is presented in Figure 7B. Taken
together, disulfiram-sunitinib cotreatment reduced prostate cancer
cell invasion and growth in 3D spheroid model.
Discussion
In this study, we utilized a chemical biology compound
sensitizing screen to study aldehyde dehydrogenase (ALDH)
inhibitor disulfiram mechanism of action and to identify potential
synergistic agents for disulfiram in TMPRSS2-ERG positive
prostate cancer cells. Total of 3357 compounds including current
chemotherapeutics and small molecular compounds were screened
alone and in combination with disulfiram and the synergistic
Figure 7. Disulfiram-sunitinib combination reduces PC-3 spheroid growth and invasion. A) Cell morphology in 3D spheroid assay in
response to compound exposures. B) The area of cells in the Incucyte images (% of total area) in response to compound treatments. Asterisks indicate
the statistical significance: *, P,0.05.
doi:10.1371/journal.pone.0051470.g007
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mechanism for disulfiram sensitizer sunitinib was studied in more
detail.
The results from the high-throughput combinatorial screen
indicated that several androgenic compounds as well as an
antioxidant astaxanthin were among compounds rescuing di-
sulfiram induced anti-proliferative effect in prostate cancer cells.
Our previous results indicated that disulfiram induced oxidative
stress in prostate cancer cells [2]. Disulfiram increases ROS levels
also in breast cancer cells [13]. Thus, the rescue effect of
antioxidant astaxanthin in disulfiram exposed cells supports the
previous results indicating that disulfiram reduced cell prolifera-
tion is mediated via induction of oxidative stress. The screening
results also suggested that PKC plays a role in disulfiram response
since PKC activator phorbol 12-myristate 13-acetate was among
drugs sensitizing to disulfiram effect whereas PKC inactivator
dequalinium analog, C-14 linker rescued disulfiram effect in the
screen. Moreover, inhibition of receptor tyrosine kinases, protea-
some, topoisomerase II, glucosylceramide synthase may be
alternative ways to enhance disulfiram effect whereas inhibition
of epidermal growth factor receptor has an opposite effect. One of
the six compounds sensitizing VCaP cells to disulfiram induced
anti-proliferative effect was antiangiogenic agent, tyrosine-protein
kinase receptor inhibitor sunitinib. Sunitinib is an anticancer drug
that is clinically used to treat metastatic renal cell carcinoma and
gastrointestinal cancer patients. It has also been shown to have
anti-neoplastic activity in hepatocellular cancer, pancreatic neu-
roendocrine tumors, and non-small cell lung cancer [18–20].
However, despite the promising results derived from in vitro and
in vivo studies as well as from phase I and II clinical trials, the phase
III trial in advanced castration-resistant prostate cancer was
recently halted due to the lack of efficacy [21,22] (identifier:
NCT00676650). Since sunitinib had already been studied in
prostate cancer clinical trials, the mechanism of disulfiram-
sunitinib combination was studied in more detail.
In this study, disulfiram-sunitinib co-exposure was shown to
reduce prostate cancer cell growth more than either of the
compounds alone. Moreover, disulfiram-sunitinib cotreatment
induced apoptosis whereas neither of the compounds alone
promoted programmed cell death in TMPRSS2-ERG fusion
positive VCaP prostate cancer cells. Our results suggest that
reduced AR signalling may play a role in disulfiram-sunitinib co-
treatment induced anti-proliferative response in prostate cancer
cells since disulfiram alone had no effect on AR nor PSA
expression while reduced AR and PSA levels were seen in sunitinib
and disulfiram-sunitinib exposures. Interestingly, sunitinib has
been known to reduce PSA levels in castration-resistant prostate
cancer patients [30].
The cell phenotypical analysis revealed that disulfiram-sunitinib
co-treatment induced cell attachment and epithelial cell differen-
tiation marker E-cadherin protein expression. Moreover, combi-
nation exposure decreased prostate cancer cell migration and
invasion in 2D and 3D cultures. Interestingly, in 3D prostate
cancer cell invasion assay, disulfiram exposed cells kept their
spheroidal conformation while luminal cells in the spheroids were
able to proliferate. In contrast, sunitinib exposed spheroids were
smaller than control exposed spheroids, but the cells were able to
invade from the spheroid structures. The disulfiram-sunitinib
combination exposure reduced cell number as well as caused
formation of smaller spheroids which were not as invasive as
control spheroids. Thus, our results suggest that disulfiram-
sunitinib combination induces prostate cancer cell attachment
and differentiation as well as reduces metastatic properties.
Interestingly, sunitinib, as well as other antiangiogenic agents,
have recently been reported to induce breast cancer chemoresis-
tance through induction of cancer stem cells [31]. The authors
suggested that the effectiveness of antiangiogenic agents could be
potentiated with drugs that target cancer stem cells. Our results
support this hypothesis, since the antiangiogenic agent sunitinib
was potentiated by ALDH and cancer stem cell inhibitor
disulfiram in prostate cancer cells. ALDH is a known marker of
cancer stem cells and its inhibition reduces chemotherapy and
radiation resistance in breast cancer [32]. Moreover, in a recent
report of a hepatocellular carcinoma patient, sunitinib was shown
to induce epithelial-to-mesenchymal transition (EMT) and thus
caused chemotherapeutic resistance [33].
Taken together, the results of this study propose novel
combinatorial means to target prostate cancer cells. Based on
the validation results, we reveal disulfiram-sunitinib combination
as a potent way to target prostate cancer cells. In addition to the
high-throughput screen in 2D cell culture, the validation studies
were done in 3D prostate cancer spheroid model recapitulating
more the in vivo tumor growth than 2D cell culture. However, we
emphasize that further in vivo preclinical and clinical studies are
needed to validate these cell-based results. The advantage in this
disulfiram-sunitinib combination approach is, that since both
agents are already in human use and considered as potential
prostate cancer inhibitors, translation of these results towards
clinical trials could be relatively fast. Furthermore, our results
provide further support for the hypothesis that antiangiogenic
agents used in combination with drugs targeting cancer stem cells
is a potent approach to prevent tumor growth and expansion.
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